Key result
Pharmacologic therapy remains first-line for hypertrophic cardiomyopathy, while surgical septal myectomy and alcohol septal ablation may be considered in symptomatic obstructive patients.
Why the study?
Patients with hypertrophic cardiomyopathy must weigh the benefits and risks of alcohol septal ablation and surgical septal myectomy using the best available current evidence, prompting a summary of recent developments in diagnosis and therapy.
Answers are grounded in this paper and cite their sources.
Supports pharmacologic first-line management in HCM; leaves open optimal selection and timing for septal reduction therapies.
Hypertrophic cardiomyopathy (HCM) has a variable clinical presentation and penetrance. Many patients will have a benign course, but others will become symptomatic and develop left ventricular outflow tract obstruction. Echocardiograph remains the standard for diagnosis and assessment of obstruction, but gains are being made in the our understanding of the genetic basis of this condition. Pharmacologic therapy remains the first-line therapy in the majority of patients, but alcohol septal ablation and surgical septal myectomy may be considered in many patients. Patients should assess both the benefits and risks of each procedure based on the best available current evidence. This paper summarizes important recent developments in HCM diagnosis and therapy.
No takes yet. Share an insight, caveat, or question.
Brown et al. (2008) conducted a review in Hypertrophic cardiomyopathy. Surgical septal myectomy and alcohol septal ablation vs. Pharmacologic therapy was evaluated. Pharmacologic therapy remains first-line for hypertrophic cardiomyopathy, while surgical septal myectomy and alcohol septal ablation may be considered in symptomatic obstructive patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: